Mibg (I123) Jobenguaan Curium Netherlands (Iodine (123i) Iobenguane)

The molecule mimics norepinephrine and is transported into adrenergic nerve endings by the norepinephrine transporter. Once inside the cells, the iodine‑123 isotope emits gamma radiation that can be captured by a gamma camera, producing images that reflect the distribution of sympathetic nerves or neuroendocrine tissue.

The administered activity of Iobenguane I-123 is determined by the prescribing physician or nuclear medicine specialist based on the patient’s weight, the imaging protocol, and regulatory guidelines. Exact dosing is individualized and should follow the institution’s standard operating procedures.

Safety data for Iobenguane I-123 in pregnancy and lactation are limited. It is generally avoided unless the diagnostic benefit outweighs potential fetal or infant risk. If administered to a nursing mother, breastfeeding may need to be paused according to local guidelines.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Iobenguane I-123 is unique in targeting the norepinephrine transporter, providing direct visualization of sympathetic nerve integrity. Other agents, such as technetium‑99m sestamibi, assess perfusion rather than innervation. Choice of agent depends on the clinical question—innervation versus perfusion—and on availability of imaging equipment.

The product must be stored at 2‑8 °C, protected from light, and kept in its original container. It should not be frozen or shaken. Handling requires radiation safety measures, including shielding, monitoring, and use of appropriate protective equipment.

Iobenguane I-123 is administered as a single intravenous injection under the supervision of a qualified nuclear medicine professional. After injection, a waiting period allows the tracer to distribute before imaging with a gamma camera, typically performed in a dedicated imaging suite.

Serious risks include severe allergic reactions (anaphylaxis), significant cardiac arrhythmias, hypotension, and radiation‑induced tissue injury such as thyroid dysfunction. These events are rare but require immediate medical attention and appropriate monitoring during and after the procedure.

Patients with known severe allergy to iodine‑123 compounds, uncontrolled thyroid disease, or those who cannot undergo gamma‑camera imaging should not receive the tracer. Additionally, individuals for whom the radiation exposure outweighs diagnostic benefit, such as certain pregnant patients, are contraindicated.